Kefazolin Versus Kefazolin Plus Metronidazole to Reduce Postpartum Infection
Randomised Trial Comparing Pre-operative Administration of Single Dose Kefazolin to Kefazolin Plus Metronidazole to Reduce Postpartum Infection
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Contact
Study Contact
- Name: Leon C Snyman, PhD
- Phone Number: +27834621818
- Email: leon.snyman@up.ac.za
Study Contact Backup
- Name: Louisa Seopela, MMed (O&G)
- Phone Number: +27833014790
- Email: drseopela@yahoo.com
Study Locations
-
-
Gauteng Province
-
Pretoria, Gauteng Province, South Africa
- Kalafong Provincial Tertiary Hospital
-
Contact:
- Leon C Snyman, PhD
- Phone Number: +27834621818
- Email: leon.snyman@up.ac.za
-
Contact:
- Louisa Seopela, MMed (O&G)
- Phone Number: +27833014790
- Email: drseopela@yahoo.com
-
Principal Investigator:
- Randy Lamfel, MBChB
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
18 years and older Willing and able to provide written informed consent
Exclusion Criteria:
- women younger than 18 years women not able or willing to provide written informed consent women with or without infection already receiving antibiotics for other indications women allergic to kefazolin or metronidazole
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Intervention arm
This arm will be allocated to receive metronidazole 500 mg in addition to the current standard of care (Kefazolin 1 or 2 grams) administered intravenously prior to skin incision at caesarean section as a once off dose
|
Metronidazole 500 mg intravenous stat dose prior to skin incision
Other Names:
|
|
Placebo Comparator: Control arm
This arm will be allocated to receive the current standard of care (Kefazolin 1 or 2 grams) administered intravenously prior to skin incision at caesarean section plus a placebo of normal saline 50 ml administered intravenously as a once off dose
|
Metronidazole 500 mg intravenous stat dose prior to skin incision
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Efficacy of reducing surgical site infection
Time Frame: Seven days post-operatively
|
Incidence of surgical site infections
|
Seven days post-operatively
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Efficacy of reducing urinary tact infections
Time Frame: Three days post-operatively
|
Incidence of urinary tract infections
|
Three days post-operatively
|
|
Efficacy of reducing postpartum endometritis
Time Frame: Seven days post-operatively
|
Incidence of endometritis
|
Seven days post-operatively
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Anticipated)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- PPS trial 1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.